Afinitor for melanoma – pro
Everolimus (RAD-001) has shown activity as a single agent and in combination in patients with metastatic melanoma unselected for potential predictive biomarkers. It had not been proven that selecting PTEN mutation is an appropriate way to increase responses. There are no randomized trials and no controlled cohort studies.
Lu Si et al, Major Response to Everolimus in Melanoma With Acquired Imatinib Resistance. Journal of Clinical Oncology 30, no. 4 (February 2012) e37-e40.
John D. Hainsworth et al, Bevacizumab and Everolimus in the Treatment of Patients With Metastatic Melanoma. A Phase 2 Trial of the Sarah Cannon Oncology Research Consortium Cancer 2010;116:41229
NCCN, Melanoma 2017
Hauke RJEverolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium.Melanoma Res. 2013 Dec;23(6):468-73